Navigation Links
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
Date:10/27/2008

MELBOURNE, Australia, Oct. 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured.

The collaboration was initially established in February 2006 by MuriGen Therapeutics and Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating factor (G-CSF).

The collaboration built on the discovery by Professor Ian Wicks, a clinical rheumatologist at the Walter and Eliza Hall Institute (WEHI) that antagonism of G-CSF or its receptor could ameliorate inflammatory conditions such as rheumatoid arthritis.

Under the terms of the restructure, CSL will now take full control of the program, including development and commercialisation of any potential drugs arising from the program. In return, MuriGen will receive certain payments - the details of which are undisclosed.

Dr Nick Samaras, MuriGen's Chief Executive Officer, said, "We are extremely pleased that the further development of the G-CSF inflammatory disease program will be conducted by an Australian biopharmaceutical partner with the expertise and capability that CSL provide. This partnership is another major milestone for MuriGen and is further evidence of the high quality portfolio the company has in-licensed from the Walter and Eliza Hall Institute. MuriGen will continue to focus on its other programs, including the development of a novel class of antiapoptotic compounds."

"This is an important step in the translation of the Institute's intellectual property," explains Dr Julian Clark, Head of Business Development at WEHI. Clark continues, "Starfish Ventures' investment in MuriGen enabled us to bring this project to a stage where CSL can now use their considerable resources and track record to progress development towards the c
'/>"/>

SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VaxGen Restructures Board of Directors
2. Genta Restructures Operations to Focus on Priority Initiatives
3. Progen Restructures Manufacturing and Drug Discovery Divisions
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. CME LLC Restructures, Announces Its New Executive Management Team
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 Ontotext ... today by Ontotext . Now the same ... analysis of structured and unstructured data is available to ... cost of enterprise technology. Organizations that do not have ... data management can use S4 since there is no ...
(Date:8/21/2014)... 2014 On Wednesday of last week RENU ... Redox Signaling molecules, became available for purchase in Australia and ... way that RENU 28 works is, if you think about ... the rate of cellular renewal within your body. If you ... that rate of cellular renewal. What RENU 28 does is ...
(Date:8/20/2014)... American Indians largely were wiped out by diseases such ... to the New World by European explorers., One report ... in the Americas shortly before Europeans arrived, and roughly ... But new research led by anthropological geneticists Anne Stone ... University of Tubingen in Germany indicates the diagnosis of ...
(Date:8/20/2014)... 20, 2014 High performance computing ... the most complete climate and Earth system model ... change issues. , Eight national laboratories, including ... National Center for Atmospheric Research, four academic institutions ... Other participating national laboratories include Argonne, Brookhaven, Lawrence ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... Seahorse Bioscience, Inc., the leader in the design and ... In Vitro Technologies Pty Ltd as the new distributor ... New Zealand. Seahorse Extracellular Flux Analyzers ... the two major energy producing pathways - mitochondrial respiration ...
... Serono, Inc., an affiliate of Merck KGaA, Darmstadt, ... response letter (CRL) from the U.S. Food and ... (NDA) for Cladribine Tablets, EMD Serono,s proprietary investigational ... relapsing-remitting multiple sclerosis (MS). (Logo: ...
... very sharp object has put Canadian researchers at the National ... Guinness Book of World Records. Only one atom at ... the sharpest man-made object. It is made of Tungsten ... currently being evaluated for its commercial potential., "We did not ...
Cached Biology Technology:Seahorse Bioscience, Inc. Appoints In Vitro Technologies Pty Ltd as New Distributor in Australia and New Zealand 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 3EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 4
(Date:8/21/2014)... standards process, will be available soon and will improve ... in the OnlineFirst version of Nutrition in Clinical ... the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.), ... misconnection that can be harmful and even fatal to ... medical devices, components, and accessories to deliver fluids or ...
(Date:8/20/2014)... a John and Rebecca Moores Professor of Biology and Biochemistry ... in the International Society for the Study of the Origin ... members two from the U.S., one from France and ... are elected every three years, and 36 have been named ... 20 countries, the ISSOL includes researchers from disciplines as varied ...
(Date:8/20/2014)... the University of Tbingen, Arizona State University, the Wellcome ... Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... 1000 years old. The pathogen is a relative of ... causes disease in humans today. These researchers assume that ... coast. "The link to sea lions was unexpected" comments ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2UH professor named fellow by International Astrobiology Society 2
... the battle of the sexes, African electric fish couples ... also engage in a sort of dueling "electric duet." ... and behavioral displays in breeding and nonbreeding Brienomyrus brachyistius, ... electric fields from a batterylike organ in their tails ...
... brain consists of billions of nerve cells enabling to ... experience, touch, smell or fear, millions of neurons in ... each other by chemical and electrical impulses to compute ... regions. With 20,000 - 25,000 genes in our genome, ...
... Board: NRGX) today announced the publication in the June 23 ... the first ever gene therapy trial for Parkinson’s disease and ... own brain cells for any adult neurodegenerative disease. , ... with advanced Parkinson’s disease demonstrated both a lack of adverse ...
Cached Biology News:Turn-ons and turn-offs for neurons 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
CD45/CD34 combination 50 tests...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
Biology Products: